SAN FRANCISCO--(BUSINESS WIRE)--Gemmus, a privately-held biotechnology company focused on the development of innovative pharmaceutical products for the treatment of influenza and other viral infectious diseases, announced today that the company has entered into an agreement with Woodside Capital Partners, retaining them as the company’s advisor and investment bank.
Help employers find you! Check out all the jobs and post your resume.
